UroGen Pharma (URGN) Total Current Liabilities (2016 - 2026)

UroGen Pharma (URGN) has reported Total Current Liabilities for 11 consecutive years, with $50.6 million the latest figure, recorded in Q1 2026.

• Quarterly Total Current Liabilities rose 20.56% year-over-year to $50.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.6 million (up 20.56% YoY) and the FY2025 annual result came in at $46.4 million, up 1.02% from the prior year.
• Total Current Liabilities climbed to $50.6 million in Q1 2026 per URGN's latest filing, from $46.4 million in the prior quarter.
• Over the last five years, Total Current Liabilities for URGN reached as high as $50.6 million in Q1 2026 and fell as low as $18.0 million in Q2 2022.
• A 5-year average of $32.8 million and a median of $31.2 million in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities retreated 5.33% — and 2025, when it surged 59.45%.
• Year by year, Total Current Liabilities stood at $23.9 million in 2022, then jumped by 30.51% to $31.2 million in 2023, then surged by 47.22% to $45.9 million in 2024, then increased by 1.02% to $46.4 million in 2025, then climbed by 9.08% to $50.6 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $50.6 million, $46.4 million, and $42.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.